首页|曲普瑞林联合腹腔镜子宫肌瘤剔除术治疗子宫肌瘤患者的效果

曲普瑞林联合腹腔镜子宫肌瘤剔除术治疗子宫肌瘤患者的效果

扫码查看
目的:观察曲普瑞林联合腹腔镜子宫肌瘤剔除术治疗子宫肌瘤患者的效果.方法:选取 2020 年 4 月至 2023 年 1 月该院收治的 96 例子宫肌瘤患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各 48 例.对照组给予腹腔镜子宫肌瘤剔除术治疗,观察组在对照组基础上联合曲普瑞林治疗.比较两组临床疗效,治疗前后子宫相关指标(子宫体积、子宫内膜血流阻力指数、子宫内膜厚度)水平、性激素指标[雌二醇(E2)、卵泡刺激素(FSH)、黄体生成素(LH)]水平,以及术后 6 个月复发率.结果:观察组治疗总有效率为 97.92%(47/48),高于对照组的 70.83%(34/48),差异有统计学意义(P<0.05);治疗后,两组子宫体积、子宫内膜厚度均小于治疗前,且观察组小于对照组,两组子宫内膜血流阻力指数均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组E2、FSH、LH水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);术后 6 个月,观察组复发率为 6.25%(3/48),低于对照组的 22.92%(11/48),差异有统计学意义(P<0.05).结论:曲普瑞林联合腹腔镜子宫肌瘤剔除术治疗子宫肌瘤患者,可提高临床疗效,缩小子宫体积和子宫内膜厚度,降低子宫内膜阻力指数和性激素指标水平,效果优于单纯腹腔镜子宫肌瘤剔除术治疗.
Effects of Triptorelin combined with laparoscopic hysteromyomectomy in treatment of patients with uterine fibroids
Objective:To observe effects of Triptorelin combined with laparoscopic hysteromyomectomy in treatment of patients with uterine fibroids.Methods:A prospective study was conducted on 96 patients with uterine fibroids admitted to this hospital from April 2020 to January 2023.According to the random number table method,they were divided into control group and observation group,48 cases in each group.The control group was treated with laparoscopic hysteromyomectomy,while the observation group was treated with Triptorelin on the basis of that of the control group.The clinical efficacy,the levels of uterine related indexes(uterine volume,endometrial blood flow resistance index,endometrial thickness)and sex hormone indexes[estradiol(E2),follicle stimulating hormone(FSH),luteinizing hormone(LH)]before and after the treatment,and the recurrence rate 6 months after the surgery were compared between the two groups.Results:The total effective rate of the observation group was 97.92%(47/48),which was higher than 70.83%(34/48)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the uterine volume and the endometrial thickness of the two groups were smaller than those before the treatment,and those in the observation group were smaller than those in the control group;the endometrial blood flow resistance index levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).The levels of E2,FSH and LH in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Further,6 months after the surgery,the recurrence rate of the observation group was 6.25%(3/48),which was lower than 22.92%(11/48)of the control group,and the difference was statistically significant(P<0.05).Conclusions:Triptorelin combined with laparoscopic hysteromyomectomy in the treatment of the patients with uterine fibroids can improve the clinical efficacy,reduce the uterine volume and the endometrial thickness,and reduce the endometrial resistance index and sex hormone index levels.Moreover,it is superior to single laparoscopic hysteromyomectomy.

TriptorelinLaparoscopic hysteromyomectomyUterine fibroidFollicle stimulating hormone

杨丹丹、周红英、李经华

展开 >

新郑华信民生医院解放路院区妇科病区,河南 郑州 451100

曲普瑞林 腹腔镜子宫肌瘤剔除术 子宫肌瘤 卵泡刺激素

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(5)
  • 12